Minervax

Minervax ApS (Copenhagen, Denmark) develops a novel vaccine candidate against Group B Streptococci (GBS). 

GBS is the leading cause of life-threatening bacterial infections in newborn babies affecting some 8,000 babies annually in Europe and the US.

GBS infections may result in still-births, or pneumonia, septicaemia and meningitis in the newborn babies leading to either severe morbidity, mortality or life-long disabilites.

The National Institute of Health of the US has identified prevention of GBS in newborns as a major vaccine objective, but so far no approved or universally useful vaccine exists.

A general vaccine effective against relevant strains of GBS could potentially be administered to pregnant women or adolescent women as part of a general vaccine program. Minervax’ GBS vaccine candidate is currently in clinical phase 2 development.

http://minervax.com/

For more information, please contact:

Sten Verland, PhD MSc

General Partner

Phone: +45 2422 1969